<DOC>
	<DOC>NCT02342158</DOC>
	<brief_summary>PERMED01 is a prospective monocenter clinical trial which aims to evaluate the number patients with locally advanced or metastatic cancer for whom identification of molecular alterations in tumor samples can lead to the delivery of a targeted therapy. PERMED01 will enroll 460 patients in 3 years.</brief_summary>
	<brief_title>Identifying Molecular Alterations to Guide Individualized Treatment in Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Age&gt;18 years Histological diagnosis of cancer Locally advanced or metastatic, biopsiable disease ECOG Performans Status â‰¤2 Affiliation to social security Signed informed consent. Emergency, Individually deprived of liberty or placed under the authority of a tutor Patients with symptomatic or progressive brain metastasis Patients who have only bone and/or brain metastases Pregnant or breastfeeding women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>